Eli Lilly reported impressive third-quarter results, boosted by tirzepatide. The company’s stock is now more appealing due to its current lineup and pipeline. Eli Lilly is also aiming to lead in AI within its industry. The company’s revenue for the quarter was $17.6 billion, with non-GAAP earnings per share at $7.02, 495% higher than the previous year. Tirzepatide’s revenue doubled to $10.1 billion compared to Q3 2024. Eli Lilly expects revenue of $63 billion to $63.5 billion for fiscal year 2025, indicating a 40.6% year-over-year growth at the midpoint.

Eli Lilly is focusing on the weight management market with a new oral GLP-1 candidate, orforglipron, which could be approved by early next year. The company is also exploring retatrutide, a promising weight management drug. The deal with the White House to lower Mounjaro and Zepbound prices for Medicare and Medicaid patients may not significantly impact the company’s financial results.

In oncology, Eli Lilly’s breast cancer medicine, Verzenio, generated $1.5 billion in sales in the third quarter. The company also received approval for Inluriyo, a new breast cancer therapy in the U.S. Additionally, Eli Lilly is venturing into AI technology, partnering with Nvidia to develop an AI supercomputer for drug development. This initiative could streamline processes, cut costs, and enhance competitiveness in the long term.

Eli Lilly’s recent performance and strategic moves make it a compelling investment opportunity. Despite the agreement to lower certain drug prices, the company’s innovative pipeline and strong financial results position it for continued growth. With a focus on weight management, oncology advancements, and AI integration, Eli Lilly remains a strong buy for investors looking for long-term potential.

Read more at Yahoo Finance: This Unstoppable Growth Stock Just Gave Investors More Reasons to Buy